In 2012, it was estimated that nearly 1 in 4 Canadians suffer from allergic rhinitis. To add, 78% of individuals working in predisposing environments are predicted to develop occupational rhinitis. Currently, the most popular treatment for rhinitis is antihistamine medication such as diphenhydramine, a first-generation antihistamine sold commercially as Benadryl®. Due it its anticholinergic effects, diphenhydramine has been suggested to impair the whole body sweating response during heat stress, potentially leaving consumers at an increased risk of heat-related illness. This randomized control trial approved by Health Canada will investigate whether ingesting extra strength diphenhydramine (50mg) will alter whole-body sweat losses during 60 minutes of exercise.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
20
A placebo pill (i.e., sugar) will be consumed 2 h before intervention.
Extra strength Benadryl (DIN 02470144) will be consumed 2 h before intervention
Lakehead Unviersity
Thunder Bay, Ontario, Canada
Whole body sweat loss
Change in body mass from pre- to post-exercise corrected for respiratory and metabolic water losses using a digital platform scale accurate to +/- 2 grams.
Time frame: Measured during both placebo and diphenhydramine intervention trials trials, separated by no more than 28 days
Change in rectal temperature
Change in rectal temperature from pre- to post- exercise using a pediatric grade thermistor
Time frame: Measured during both placebo and diphenhydramine intervention trials trials, separated by no more than 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.